Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:29:47 30/04/2024 pm IST			5-day change	1st Jan Change
902.6 ^DKK	+2.01%		+1.27%	+29.29%

10:02pm	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
09:56pm	Sector Update: Health Care	MT

NOVO NORDISK : Gets a Buy rating from JP Morgan

August 05, 2021 at 12:07 pm IST

Richard Vosser from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price has been raised to DKK 700 from DKK 500.

Latest news about Novo Nordisk A/S

Sector Update: Health Care Stocks Mixed Late Afternoon	01:32am	MT
Sector Update: Health Care	01:26am	MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	09:31pm	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	09:21pm	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	08:31pm	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	08:20pm	MT
One dose of Novo Nordisk's Wegovy back in supply, FDA website shows	29/04	RE
Big tech saves the day, again	29/04
NOVO NORDISK : UBS sticks Neutral	29/04	ZD
NOVO NORDISK : JP Morgan gives a Buy rating	25/04	ZD
Scholz promises support for pharma sector in Germany as Merck invests	25/04	RE
Sector Update: Health Care Stocks Slipping Late Afternoon	25/04	MT
Sector Update: Health Care	25/04	MT
Novo Nordisk's Wegovy FDA Approval for Heart Health Opens Door to Medicare Access, KKF Says	25/04	MT
US Senate committee investigates pricing of Novo's Ozempic and Wegovy	24/04	RE
Novo Nordisk Probed by Senate Committee on Weight-Loss Drug Prices	24/04	DJ
NOVO NORDISK : Bernstein maintains a Buy rating	24/04	ZD
Germany's Evotec appoints Christian Wojczewski as CEO	24/04	RE
UK stocks may finally be back in fashion	23/04	RE
Health Care Climbs on Earnings Hopes -- Health Care Roundup	23/04	DJ
Eli Lilly to acquire manufacturing facility from Nexus Pharma	22/04	RE
India's Biocon developing its own version of Wegovy, clinical trial likely next year	18/04	RE
More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm	15/04	RE
Biophytis: patent application filed in the field of obesity	15/04	CF
Health Care Falls as Risk Aversion Weighs on Obesity Drug Makers -- Health Care Roundup	13/04	DJ

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

02/05/2024 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVO NORDISK : Novo’s bag is full of pearls!

March 15, 2024 at 02:52 pm IST

Kasim Kutay, CEO of Novo Holdings: Catalent purchase marks new era of acquisitions

March 12, 2024 at 04:51 pm IST

Novo Nordisk doesn't disappoint

January 31, 2024 at 09:18 pm IST

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

884.8 DKK

Average target price

904.2 DKK

Spread / Average Target

+2.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+29.29%	567B
ELI LILLY AND COMPANY	+34.26%	664B
JOHNSON & JOHNSON	-7.68%	354B
MERCK & CO., INC.	+18.49%	330B
ABBVIE INC.	+4.99%	286B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.79%	148B
PFIZER, INC.	-10.89%	145B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Gets a Buy rating from JP Morgan

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals